Friday, March 10, 2023 10:10:41 AM
Pivot Point 2nd Level Resistance 0.8933
1-Month High 0.8550
Pivot Point 1st Resistance Point 0.8467
High 0.8100
Previous Close 0.8000
Last 0.7899
Low 0.7810
Pivot Point 1st Support Point 0.7617
Pivot Point 2nd Support Point 0.7233
Pivot Point 3rd Support Point 0.6767
Recent NRBO News
- NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in June • PR Newswire (US) • 04/30/2024 12:01:00 PM
- NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity • PR Newswire (US) • 04/17/2024 12:05:00 PM
- NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH • PR Newswire (US) • 04/01/2024 12:01:00 PM
- NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update • PR Newswire (US) • 03/28/2024 12:01:00 PM
- NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH • PR Newswire (US) • 03/13/2024 12:01:00 PM
- NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer • PR Newswire (US) • 03/04/2024 01:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 12:30:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 01:30:14 PM
- NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity • PR Newswire (US) • 02/29/2024 01:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 01:52:22 PM
- NeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor Conference • PR Newswire (US) • 02/12/2024 01:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:15 PM
- NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity • PR Newswire (US) • 02/01/2024 01:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/18/2024 01:30:23 PM
- NeuroBo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of DA-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH • PR Newswire (US) • 01/18/2024 01:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/09/2024 01:45:11 PM
- NeuroBo Pharmaceuticals Regains Compliance with Nasdaq Minimum Price Requirement • PR Newswire (US) • 01/09/2024 01:30:00 PM
- NeuroBo to Participate in Industry and Investor Conferences in January • PR Newswire (US) • 01/02/2024 01:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 02:00:14 PM
- NeuroBo Pharmaceuticals Submits IND Application to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity • PR Newswire (US) • 12/28/2023 01:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2023 02:03:45 PM
- NeuroBo Pharmaceuticals Announces 1-for-8 Reverse Stock Split • PR Newswire (US) • 12/19/2023 01:43:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/07/2023 02:20:48 PM
- NeuroBo to Participate in Investor Conferences in December • PR Newswire (US) • 12/01/2023 01:31:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:29:02 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM